title: [Bevacizumab. Progress in cancer therapy by antiangiogenesis].
abstract: Bevacizumab represents the first humanized monoclonal antibody with antiangiogenic properties which has been introduced in clinical oncology. The VEGF antagonist is used for the treatment of advanced colorectal cancer based on significant survivial benefits. Besides hypertension, proteinuria, wound healing disorders, bleeding and thromboembolic events appear to be related to bevacizumab. Optimization of combination therapy, new potential indications as well as pharmacoeconomic considerations represent the topics of current discussion regarding the novel monoclonal antibody.
authors.affiliation: Apotheke des Klinikums der Johannes Gutenberg-Universität Mainz, Langenbeckstrasse 1, 55131 Mainz.
authors.forename: Irene
authors.initials: I
authors.lastname: Krämer
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Lipp
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D040262:Receptors, Vascular Endothelial Growth Factor / Q000187:drug effects
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor